Anthem Biosciences (NSE:ANTHEM) Total Equity: ₹30,425 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ANTHEM Anthem Biosciences Ltd NSE:ANTHEM
24 GF Score
Price ₹758.95
! 2 Warning Signs
View Full Analysis

What is Anthem Biosciences Total Equity?

Anthem Biosciences NSE:ANTHEM +1.09% 24 Total Equity is ₹30,425 Mil as of Mar. 2026. GuruFocus rates NSE:ANTHEM with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Anthem Biosciences's total equity for the quarter that ended in Mar. 2026 was ₹30,425 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Anthem Biosciences Total Equity Historical Data

* Premium members only.

The historical data trend for Anthem Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthem Biosciences Total Equity Chart

Anthem Biosciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
13,549.98 17,406.68 19,246.55 24,098.64 30,425.16

Anthem Biosciences Quarterly Data
Mar22 Mar23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only 0.00 24,098.64 27,525.45 0.00 30,425.16
NSE:ANTHEM
24GF Score
Anthem Biosciences Ltd NSE:ANTHEM
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anthem Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Anthem Biosciences's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=34292.9-3867.74
=30,425

Anthem Biosciences's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=34292.9-3867.74
=30,425

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹30,425 Mil mean?
Anthem Biosciences (NSE:ANTHEM) has a Total Equity of ₹30,425 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Anthem Biosciences and its competitors.
Is Anthem Biosciences' Total Equity too high?
Anthem Biosciences' current Total Equity is ₹30,425 Mil. Overall, Anthem Biosciences has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' Total Equity compare to VRTX and REGN?
Anthem Biosciences' Total Equity of ₹30,425 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Anthem Biosciences and its competitors. Anthem Biosciences's current Total Equity is ₹30,425 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current Total Equity of ₹30,425 Mil. The current Total Equity is ₹30,425 Mil. Anthem Biosciences' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current Total Equity is ₹30,425 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anthem Biosciences Business Description

Other Exchanges 544449:India
Address No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bangalore, KA, IND, 560 099
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
24GF Score

Get the complete analysis for NSE:ANTHEM

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹758.95
Price